Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

Travere Therapeutics, Inc. announced the US FDA has accepted and granted Priority Review of its New Drug Application under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy.